Netherlands · Delayed Price · Currency is EUR Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of EUR 837.62 million. The enterprise value is 790.81 million.
| Market Cap | 837.62M |
| Enterprise Value | 790.81M |
Important Dates
The last earnings date was Thursday, May 7, 2026.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 706.25 million shares outstanding. The number of shares has increased by 13.48% in one year.
| Current Share Class | 706.25M |
| Shares Outstanding | 706.25M |
| Shares Change (YoY) | +13.48% |
| Shares Change (QoQ) | -1.64% |
| Owned by Insiders (%) | 1.55% |
| Owned by Institutions (%) | 20.87% |
| Float | 695.28M |
Valuation Ratios
The trailing PE ratio is 83.82 and the forward PE ratio is 42.93.
| PE Ratio | 83.82 |
| Forward PE | 42.93 |
| PS Ratio | 2.61 |
| PB Ratio | 3.59 |
| P/TBV Ratio | 7.00 |
| P/FCF Ratio | 17.33 |
| P/OCF Ratio | 17.12 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.72, with an EV/FCF ratio of 16.36.
| EV / Earnings | 73.79 |
| EV / Sales | 2.47 |
| EV / EBITDA | 19.72 |
| EV / EBIT | 25.77 |
| EV / FCF | 16.36 |
Financial Position
The company has a current ratio of 2.63, with a Debt / Equity ratio of 0.43.
| Current Ratio | 2.63 |
| Quick Ratio | 2.05 |
| Debt / Equity | 0.43 |
| Debt / EBITDA | 2.54 |
| Debt / FCF | 2.09 |
| Interest Coverage | 4.20 |
Financial Efficiency
Return on equity (ROE) is 5.04% and return on invested capital (ROIC) is 10.00%.
| Return on Equity (ROE) | 5.04% |
| Return on Assets (ROA) | 4.89% |
| Return on Invested Capital (ROIC) | 10.00% |
| Return on Capital Employed (ROCE) | 9.25% |
| Weighted Average Cost of Capital (WACC) | 4.86% |
| Revenue Per Employee | 787,361 |
| Profits Per Employee | 26,332 |
| Employee Count | 407 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 0.71 |
Taxes
In the past 12 months, Pharming Group has paid 6.65 million in taxes.
| Income Tax | 6.65M |
| Effective Tax Rate | 38.57% |
Stock Price Statistics
The stock price has increased by +25.75% in the last 52 weeks. The beta is 0.12, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | +25.75% |
| 50-Day Moving Average | 1.34 |
| 200-Day Moving Average | 1.34 |
| Relative Strength Index (RSI) | 42.03 |
| Average Volume (20 Days) | 13,552,038 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharming Group had revenue of EUR 320.46 million and earned 10.72 million in profits. Earnings per share was 0.01.
| Revenue | 320.46M |
| Gross Profit | 282.45M |
| Operating Income | 30.26M |
| Pretax Income | 17.24M |
| Net Income | 10.72M |
| EBITDA | 36.67M |
| EBIT | 30.26M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 147.59 million in cash and 100.78 million in debt, with a net cash position of 46.81 million or 0.07 per share.
| Cash & Cash Equivalents | 147.59M |
| Total Debt | 100.78M |
| Net Cash | 46.81M |
| Net Cash Per Share | 0.07 |
| Equity (Book Value) | 233.27M |
| Book Value Per Share | 0.31 |
| Working Capital | 158.86M |
Cash Flow
In the last 12 months, operating cash flow was 48.94 million and capital expenditures -611,447, giving a free cash flow of 48.33 million.
| Operating Cash Flow | 48.94M |
| Capital Expenditures | -611,447 |
| Depreciation & Amortization | 6.35M |
| Net Borrowing | -14.18M |
| Free Cash Flow | 48.33M |
| FCF Per Share | 0.07 |
Margins
Gross margin is 88.14%, with operating and profit margins of 9.44% and 3.34%.
| Gross Margin | 88.14% |
| Operating Margin | 9.44% |
| Pretax Margin | 5.38% |
| Profit Margin | 3.34% |
| EBITDA Margin | 11.44% |
| EBIT Margin | 9.44% |
| FCF Margin | 15.08% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.48% |
| Shareholder Yield | -13.48% |
| Earnings Yield | 1.28% |
| FCF Yield | 5.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.
| Last Split Date | Mar 5, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Pharming Group has an Altman Z-Score of 3.19 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.19 |
| Piotroski F-Score | 5 |